Table 1.
Comparison of clinical and laboratory variables between MetS patients with LDL-c within and above target.
| n | LDL-c within target (n = 61) | n | LDL-c above target (n = 116) | p | |
|---|---|---|---|---|---|
| Female n (%) | 61 | 25 (41%) | 116 | 53 (45.7%) | 0.549 |
| Age (years) | 61 | 54.6 ± 13.1 | 116 | 54.1 ± 11.7 | 0.790 |
| Body mass index (Kg/m2) | 47 | 29.9 ± 3.8 | 93 | 30.5 ± 4.8 | 0.465 |
| Systolic BP (mmHg) | 56 | 140.0 ± 17.0 | 102 | 138.2 ± 18.5 | 0.535 |
| Diastolic BP (mmHg) | 45 | 79.4 ± 12.6 | 74 | 80.8 ± 13.6 | 0.571 |
| Waist circumference (M) (cm) | 19 | 103.5 ± 9.0 | 23 | 105.0 ± 11.2 | 0.653 |
| Waist circumference (F) (cm) | 10 | 104.4 ± 13.6 | 23 | 100.3 ± 9.0 | 0.310 |
| Triglycerides* (mg/dL) | 61 | 174.0 (122.5–302.5) | 116 | 165.5 (110.0–239.2) | 0.299 |
| HDL-c (M) (mg/dL) | 36 | 35.8 ± 10.3 | 63 | 39.2 ± 10.3 | 0.117 |
| HDL-c (F) (mg/dL) | 25 | 44.9 ± 11.4 | 53 | 43.2 ± 12.1 | 0.545 |
| Glucose* (mg/dL) | 55 | 102.0 (90.0–125.0) | 103 | 111.0 (94.0–156.0) | 0.062 |
| A1c (%) | 33 | 6.5 ± 1.6 | 65 | 7.4 ± 1.8 | 0.024 |
| Uric acid (mg/dL) | 41 | 5.5 ± 1.7 | 73 | 5.4 ± 1.7 | 0.820 |
| Homocysteine (µmol/L) | 47 | 15.8 ± 10.3 | 92 | 13.5 ± 6.5 | 0.171 |
| Diabetes n (%) | 60 | 27 (45%) | 115 | 70 (60.9%) | 0.045 |
| Statin use n (%) | 56 | 37 (66.1%) | 100 | 57 (57%) | 0.267 |
| Fibrates use n (%) | 56 | 14 (25%) | 100 | 14 (14%) | 0.086 |
| Ezetimibe use n (%) | 61 | 4 (6.5%) | 115 | 7 (6.1%) | 0.596 |
| Alcohol drinking n (%) | 36 | 11 (30.5%) | 63 | 18 (28.6%) | 0.817 |
| Smoking n (%) | 54 | 10 (18.5%) | 102 | 16 (15.7%) | 0.897 |
Data are presented as mean ± standard deviation, unless otherwise indicated by ∗corresponding to data presented as median, 25th and 75th percentiles. LDL-c = Low-density lipoprotein cholesterol; BP = Blood pressure; HDL-c = High-density lipoprotein cholesterol, M = male; F = female